The devotion to surrogate outcomes in drug development for liver disease

    loading  Checking for direct PDF access through Ovid

Abstract

Surrogate end points are often used in clinical trials where the time to clinical outcomes is long. In patients with liver disease, these surrogate outcomes are rarely validated. Without validation, treatment effects reported in trials might not directly translate to patient benefit after licensing.

Related Topics

    loading  Loading Related Articles